A syndicate of investors led by Nomura, including Global Life Science Ventures, HBM Bioventures, Novartis Bioventures and Wellcome has provided EUR 42m in financing to antibiotic research concern Nabriva GmbH. GLSV committed EUR 6m in the series A financing round. Nabriva GmbH, which was launched today as an independent concern, previously existed within Sandoz GmbH as the Vienna-based Antibiotic Research Institute (ABRI).
Anna Morrison joins from IFM Investors, where she managed the firm's fund-of-funds programme
Fund's predecessor, Isomer Capital Fund, closed on €150m in February 2016
Funding will be used to hire more staff, support product development and meet customer demand
True Core VII provides seed and early-stage capital, while True Select IV provides follow-on capital